Biotechnology startup Sol Gel Technologies is raising $8 million from existing and new investors, reports hi-tech information firm Dolev & Abramovitch.
Beit Shemesh-based Sol Gel, founded in 1997, has developed a proprietary technology to entrap organic and inorganic molecules in glass for the healthcare and environmental industries.
Its first product line consists of UV-filtering molecules encapsulated in inert cosmetically-acceptable glassine micro-spheres that do not penetrate the skin.
In March last year the company secured $3.5 million at a post-money company value of $7.8 million from Evergreen Canada Israel Investments, Apcon, and Millennium Material Funds, among others.
According to D&A, the company managed to lift its value for investment purposes since its last round.